Original Article
Reham Adly Zayed, Monir Hussei
Abstract
Aim: To estimate the prevalence of New Onset Diabetes after Liver Transplantation (NODAT) and to investigate the possible risk factors. Methods: This retrospective study comprises 213 patients subjected to living donor liver transplantation (LDLT). Patients’ data were collected from medical registry files for a period of two years after transplant. Results: Of the total 213 recipients, complete data for the whole study period were available for 164 recipients who were enrolled in this study. Fifty one 51 (31.1%) patients were already diabetic prior to transplantation. The prevalence of NODAT was 27.43% (31/113). Eight of NODAT cases (25.8%) were transient with recovery within 6-months period in 5/8 cases while the other 3 cases recovered in more than 6 months to a year. The only drug that showed statistically significant difference was tacrolimus (p=0.02). Interestingly, three pre-transplant diabetics (3/51, 5.9%) recovered after liver transplant with elimination of their anti-diabetic therapy. Conclusion: NODAT is a common medical complication that occurs in 27.4% of liver transplant recipients. The study suggests using one year cutoff rather than 6 months for defining transient NODAT. Post-transplant tacrolimus-based immunosuppression is a significant independent predictor of NODAT development